Mason has RAC cited this paper?
I think only you have cited it.
As you point out, it's even more relevant than the Yang paper.
RAC must be aware of it.
I guess RAC is unwilling to give DAC51 any publicity.
The main way in which DAC51 is inferior isn't its lower potency; it's the lack of clinical data.
Unlisted Options Transactions, page-179
-
- There are more pages in this discussion • 29 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.53 |
Change
-0.060(3.79%) |
Mkt cap ! $259.9M | |||
| Open | High | Low | Value | Volume |
| $1.54 | $1.56 | $1.53 | $130.2K | 84.73K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 4993 | $1.53 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.58 | 10451 | 1 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |